Costs of CTA versus functional diagnostic testing for suspected coronary artery disease.
CT angiography (CTA) and functional diagnostic testing strategies in patients with suspected coronary artery disease (CAD) have similar costs, according to a study published in the Annals of Internal Medicine.
Researchers from Duke University in Durham, NC, Harvard Medical School in Boston, MA, and the National Heart, Lung, and Blood Institute in Bethesda, MD, conducted prospective economic analysis for PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain).
A total of 9,649 patients were enrolled in PROMISE between July 2010 and September 2013, and the median follow-up was 25 months. The researchers estimated technical costs of the outpatient testing strategy using the Premier Research Database; hospital-based costs were
estimated using hospital bills and Medicare cost–charge ratios; and physician fees were taken from the Medicare Physician Fee Schedule.
Mean initial testing costs were:
• Exercise electrocardiography: $174
• CTA: $404
• Pharmacologic and exercise stress echocardiography: $501 to $514, respectively
• Exercise and pharmacologic stress nuclear testing: $946 to $1,132, respectively
The mean costs at 90 days were $2,494 for the CTA strategy versus $2,240 for the functional strategy. The difference was associated with more revascularizations and catheterizations (4.25 per 100 patients) with CTA use, the researchers noted. After 90 days, the mean cost difference between the groups out to three years remained small.
The researchers concluded that CTA and functional diagnostic testing strategies in patients with suspected CAD have similar costs through three years of follow-up.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.